Top

Published in:

01-12-2019 | Case Report

Recurrent Pancreatitis Secondary to Diffuse Large B Cell Lymphoma

Authors: Maham Hayat, Taseen A. Syed, Molly Disbrow, Ngoc Thy Bao Tran, Zain Ul Abideen Asad, William M. Tierney

Published in: Journal of Gastrointestinal Cancer | Issue 4/2019

Excerpt

Pancreatic lymphoma is an extremely rare pancreatic tumor representing less than 0.5% of pancreatic tumors, with diffuse large B cell lymphoma (DLBCL) being the predominant type. Pancreatic involvement by B cell lymphoma has been reported in the literature; however, acute pancreatitis is a very uncommon presentation. Here, we report a case of secondary pancreatic involvement of DLBCL presenting as pancreatitis, which underscores the importance of defining the cause of unexplained recurrent pancreatitis. …

DA-EPOCH-R (Etoposide + Prednisone + Vincristine + Cyclophosphamide + Doxorubicin + Rituximab)

Hyper CVAD [Cyclophosphamide, Vincristine, Doxorubicin (which is also called Adriamycin), Dexamethasone (steroid) + Methotrexate and Cytarabine

Kiresi DA, Kivrak AS, Ecirli S, Toy H. Secondary breast, pancreatic, and renal involvement with non-Hodgkin's lymphoma: imaging findings. Breast (Edinburgh, Scotland). 2006;15(1):106–10.CrossRef

Blouhos K, Boulas KA, Paraskeva A, Kariotis I, Barettas N, Hatzigeorgiadis A. Obstructive jaundice as primary presentation of a stage IIE non-Hodgkin lymphoma: a decision making process between advanced lymphoma and locally advanced/metastatic pancreatic adenocarcinoma. Int J Surg Case Rep. 2018;44:226–9.CrossRef

Saif MW, Khubchandani S, Walczak M. Secondary pancreatic involvement by a diffuse large B-cell lymphoma presenting as acute pancreatitis. World J Gastroenterol. 2007;13(36):4909–11.CrossRef

Bernardeau M, Auroux J, Cavicchi M, Haioun C, Tsakiris L, Delchier JC. Secondary pancreatic involvement by diffuse large B-cell lymphoma presenting as acute pancreatitis: treatment and outcome. Pancreatology. 2002;2(4):427–30.CrossRef

Balagoni H, Bhogal SS, Koppurapu V, Young M. A rare case of systemic diffuse B-cell lymphoma presenting as pancreatitis. Pancreatology. 2017;17(4, Supplement):S27.CrossRef

Van Beers B, Lalonde L, Soyer P, Grandin C, Trigaux JP, De Ronde T, et al. Dynamic CT in pancreatic lymphoma. J Comput Assist Tomogr. 1993;17(1):94–7.CrossRef

Anand D, Lall C, Bhosale P, Ganeshan D, Qayyum A. Current update on primary pancreatic lymphoma. Abdom Radiol (New York). 2016;41(2):347–55.CrossRef

Merkle EM, Bender GN, Brambs HJ. Imaging findings in pancreatic lymphoma: differential aspects. AJR Am J Roentgenol. 2000;174(3):671–5.CrossRef

Dong A, Cui Y, Gao L, Wang Y, Zuo C, Yang J. Patterns of FDG uptake in pancreatic non-Hodgkin's lymphoma lesions. Abdom Imaging. 2014;39(1):175–86.CrossRef

10.

Johnson EA, Benson ME, Guda N, Pfau PR, Frick TJ, Gopal DV. Differentiating primary pancreatic lymphoma from adenocarcinoma using endoscopic ultrasound characteristics and flow cytometry: a case-control study. Endoscopic Ultrasound. 2014;3(4):221–5.CrossRef

11.

Krishna NB, LaBundy JL, Saripalli S, Safdar R, Agarwal B. Diagnostic value of EUS-FNA in patients suspected of having pancreatic cancer with a focal lesion on CT scan/MRI but without obstructive jaundice. Pancreas. 2009;38(6):625–30.CrossRef

12.

Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2015;26(suppl_5):v116–v25.CrossRef

Title: Recurrent Pancreatitis Secondary to Diffuse Large B Cell Lymphoma
Authors: Maham Hayat
Taseen A. Syed
Molly Disbrow
Ngoc Thy Bao Tran
Zain Ul Abideen Asad
William M. Tierney
Publication date: 01-12-2019
Publisher: Springer US
Published in: Journal of Gastrointestinal Cancer / Issue 4/2019
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-018-0175-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2019

Impact of Prior Malignancy on Survival Outcomes of Stage IV Pancreatic Adenocarcinoma: SEER-Based Cohort

Undifferentiated Embryonal Sarcoma of the Liver: a Great Masquerader

Late-Onset Lung Metastasis in Rectum Cancer Can Be Confused with Primary Lung Cancer; a Case Report and Literature Review

Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?

Hepatocellular Carcinoma with Orbital Metastasis: a Unique Multidisciplinary Case Report

Von Meyenburg Complexes Mimicking Diffuse Metastatic Liver Disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials